Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Infinity Advances IPI-549 to Phase 1 Study - Enrollment in Dose Escalation Study Began February 2016

Source Link:: http://seekingalpha.com/article/3922866-infinity-pharmaceuticals-infi-ceo-adelene-perkins-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

INFI

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details IPI-549 is a small molecular development candidate in anti-tumor immunity by selectively inhibiting PI3 kinase-gamma. Infinity began enrolling patients in our Phase 1 trial of IPI-549 last month. The trial is a robust study design to explore the dose safety and activity of 549.

http://seekingalpha....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Feb 15, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Ipi-549, Phase 1 Study, Dose Escalation, Anti-tumor Immunity, Pi3 Kinase-gamma